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could be a target for therapies aiming at promoting remy-
elination in demyelinating disease.
Keywords Remyelination · EphrinB3 · 
Oligodendrocytes · Multiple sclerosis
Introduction
Myelin sheaths are layered, lipid-rich structures that wrap 
around axons to mediate salutatory signal conduction along 
them and provide them with trophic support [38, 45]. In the 
central nervous system (CNS), myelin sheaths are formed by 
oligodendrocytes [9]. Myelin is a target of demyelinating dis-
eases, such as multiple sclerosis (MS) [22, 30]. In response 
to myelin degeneration, multipotent parenchymal progeni-
tor cells called oligodendrocyte progenitor cells (OPCs) are 
activated and recruited to the damaged areas [22]. These can 
regenerate myelin to some extent, but the process is often 
incomplete [35], leaving axons permanently demyelinated and 
vulnerable to degeneration [6].
Abstract Remyelination in multiple sclerosis (MS) 
lesions often remains incomplete despite the presence of 
oligodendrocyte progenitor cells (OPCs). Amongst other 
factors, successful remyelination depends on the phago-
cytic clearance of myelin debris. However, the proteins in 
myelin debris that act as potent and selective inhibitors on 
OPC differentiation and inhibit CNS remyelination remain 
unknown. Here, we identify the transmembrane signalling 
protein EphrinB3 as important mediator of this inhibition, 
using a protein analytical approach in combination with a 
primary rodent OPC assay. In the presence of EphrinB3, 
OPCs fail to differentiate. In a rat model of remyelination, 
infusion of EphrinB3 inhibits remyelination. In contrast, 
masking EphrinB3 epitopes using antibodies promotes 
remyelination. Finally, we identify EphrinB3 in MS lesions 
and demonstrate that MS lesion extracts inhibit OPC dif-
ferentiation while antibody-mediated masking of EphrinB3 
epitopes promotes it. Our findings suggest that EphrinB3 
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The reason for remyelination failure in MS is still not 
fully understood, and is expected to be complex. Several 
studies have demonstrated that a proportion of chronically 
demyelinated MS lesions contains OPCs that fail to dif-
ferentiate into remyelinating oligodendrocytes [10, 30, 32, 
52]. It is likely that intrinsic changes in OPCs as well as 
extrinsic inhibitors, such as chondroitin sulphate proteo-
glycans, that accumulate in MS lesions, contribute to the 
differentiation failure of OPCs in MS [1, 5, 12, 20, 23, 24, 
28–30, 34, 46, 49].
We and others have demonstrated that successful remy-
elination is dependent on an active inflammatory response 
[5, 30], and especially the presence of macrophages [29]. 
The switch from proliferation-inducing M1 macrophages to 
M2 type activation may promote OPC differentiation [37]. 
Experimental studies of remyelination indicate that the role 
of macrophages in remyelination is twofold: first, mac-
rophages contribute by secretion of cytokines and second, 
by the phagocytic clearance of myelin debris [31, 37]. The 
elimination of myelin debris is an important prerequisite 
for remyelination. Studies in primary rodent OPC cultures 
have demonstrated that unknown proteins in myelin exert 
potent and selective inhibitory effects on OPC differentia-
tion [2, 41, 48]. Furthermore, supplementation of experi-
mentally induced demyelinated lesions with myelin debris 
results in a nearby complete suppression of remyelination 
in vivo without affecting the presence of OPC response 
[28]. Electron micrographs of biopsies of acute MS lesions 
[30] and proteomic analysis of MS lesions postmortem 
indicated that myelin proteins may accumulate and persist 
in MS lesions [26]. In the present study, we sought to iden-
tify the molecular substrate in myelin that is responsible for 
inhibiting OPC differentiation, and to determine whether 
neutralization of myelin inhibitors may constitute a novel 
target for remyelination therapies.
Materials and methods
Ethics statement
All animal experiments were conducted in accordance 
with animal welfare regulations of the German animal 
protection law, the Niedersächsisches Landesamt fur 
Verbraucherschutz und Lebensmittelsicherheit (license: 
RKO_033/2008), Max Planck Institute, UK home office 
and ARRIVE guidelines.
Characterization of chronic active MS lesions
Postmortem MS lesion tissue was provided by the UK 
MS tissue bank. Chronic active lesions were identified by 
H&E staining and defined by the presence of immune cells 
(HLA + T-lymphocytes) and the absence of foamy mac-
rophages. Active lesions contained foamy macrophages.
Immunohistochemistry of MS lesions
Immunohistochemistry on MS lesions was performed as 
described in [50]. Sections were stained with antibodies to 
Nkx2.2 (1:150) and β3tubulin (1:500), HLA (1:150), MBP 
(1:300), GFAP (1:500) degenerated MBP (1:500). Appro-
priate Alexa 488, 555 or 594-conjugated secondary anti-
bodies (Invitrogen) were used. Cell nuclei were visualized 
with DAPI (Sigma-Aldrich). A list with details of the anti-
bodies used is included in Supplementary Table 8.
Laser capture microdissection
MS lesions were visualized on 30 µm cryostat sections 
by rapid immunohistochemistry with antibodies to MOG 
(1:20). MOG-negative lesions cores were harvested by 
laser capture microdissection (P.A.L.M. Microlaser Sys-
tems) and proteins were extracted using Lysis buffer (8 M 
urea, 4 % w/w CHAPS, 5 mM magnesium acetate, 10 mM 
Tris pH 8.0 and protease inhibitor cocktail set I at 1 × con-
centration (Calbiochem).
Preparation of myelin protein extracts (MPE)
Myelin (rat and human) was purified from mechanically 
dissociated brains by two rounds of discontinuous density 
gradient centrifugation and osmotic disintegration. Protein 
extracts were prepared by dissolving myelin pellets with 
1 % N-octyl-β-d-glucopyranoside, 0.2 M sodium phosphate 
pH 6.8, 0.1 M Na2SO4, and 1 mM ethylenediaminetet-
raacetic acid.
Enrichment of inhibitory activity in MPE by column 
chromatography
MPE (50 mg) was filtered, desalted and concentrated 
(Amicon ultrafiltration cell, Millipore) with 50 mM 
sodium acetate (pH 4). Column chromatography was 
performed by FPLC (Pharmacia Fine Chemicals, GE 
Healthcare). First, MPE was separated by cationic chro-
matography (Econo-Pac CM cartridges, 1 ml, BioRad). 
To test the resulting fractions for inhibitory activity, 
OPCs were exposed to substrates that were prepared 
using equal volumes (100 µl) of eluates, and the number 
of O4 + OPCs was determined. Further separation of 
inhibitory fractions was achieved using anionic chroma-
tography (EconoPac High Q cartridge, BioRad) and gel 
exclusion chromatography (Sephacryl S100 column, GE 
Healthcare). Protease inhibitors (Thermo Scientific) were 
used during all stages.
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Proteomic analysis of MS lesions and MPE fractions
Protein extracts were precipitated with ammonium acetate 
in methanol, separated by 1D SDS-PAGE, and stained with 
colloidal Coomassie blue. Each track was cut into 1 mm 
slices (16 per track). Mass spectrometry experiments were 
performed using an LTQ linear ion trap instrument fitted 
with a nanospray ion source (Thermo, San Jose, CA). The 
LTQ was operated in a data-dependent manner, and ions 
with a charge state of 2+ or 3+ (indicative of a tryptic pep-
tide) were automatically isolated, fragmented by CID and 
an MS/MS spectrum generated. The separation of peptides 
was performed by reverse-phase chromatography using an 
Agilent 1200 (Agilent Technologies, Santa Clara, CA), a 
HPLC pump at a flow rate of 300 nL/min and a LC-Pack-
ings (Dionex, Sunnyvale, CA) PepMap 100 column (C18, 
75 uM i.d. × 150 mm, 3 μM particle size). Peptides were 
loaded onto a LC-Packings pre-column (Acclaim PepMap 
100 C18, 5 μM particle size, 100 A, 300 μM i.d × 5 mm) 
in 0.1 % formic acid for 5 min at a flow rate of 20 μL/
min to desalt samples. A gradient employed of 5–55 % B 
in 60 min was used to elute peptides (Solvent A = 0.1 % 
formic acid in water and solvent B = 5 % acetonitrile with 
0.1 % formic acid in water). Data were processed using 
Bioworks Browser (version 3.3.1 SP1, ThermoFisher), 
and searched using MASCOT (Matrix Science Ltd) using 
a fixed modification of carbamidomethyl and a variable 
modification of oxidation (M). The databases used were 
NCBInr 060629 Rattus or Homo sapiens with a Peptide 
Mass Tolerance of ±1 Da and a Fragment Mass Tolerance 
of ±0.8 Da.
Preparation of primary OPC cultures
Primary OPC cultures were isolated from neonatal (p0–2) 
Sprague–Dawley rat forebrains as in [2, 47]. Differen-
tiation was induced with Sato’s medium containing 0.5 % 
FCS. Only cultures ≥94 % A2B5+ cells were used. OPCs 
were plated at a density of 2 × 104 cells (8-well chamber 
slides) or 3 × 105 cells (6-well plates).
Immunocytochemistry
Immunocytochemistry on OPCs was conducted as in. 
O4, Nkx2.2, Mbp-positive cells were quantified rela-
tive to DAPI-stained nuclei in >20 randomly selected eye 
fields on an Olympus X80 microscope. The morphology 
of OPCs stained with phalloidin was categorized as fol-
lows: I: mono/bipolar; II: multipolar, primary branches; 
III: multipolar, secondary branches; IV: membranous 
processes.
Preparation of MS lesion, MPE, and EphrinB3 
substrates
MS lesion extract (see below), MPE and EphrinB3-Fc 
(R&D) substrates were prepared by overnight incubation 
on PLL (Sigma-Aldrich) coated dishes as in [48, 49].
Pre‑clustering of recombinant EphrinB3‑Fc
EphrinB3-Fc fragments were mixed with anti-human Fc-
IgG (Millipore) (ratio = 1:5) and incubated for 2 h at room 
temperature prior to addition to the tissue culture medium.
Effects of EphrinB3 on late‑stage OPCs
OPCs were differentiated in Sato’s differentiation medium 
for 48 h, and subsequently exposed to pre-clustered 
EphrinB3 suspended in Sato’s medium for another 24 h. 
Cells were then fixed with 4 % PFA and assessed for O4 
and Mbp expression.
Neutralization of EphrinB3 epitopes in MPE
EphrinB3 epitopes in MPE substrates and MS lesion 
extracts were neutralized by incubation with anti-EphrinB3 
antibodies (Abcam and R&D; ratio: 1:1) in Sato’s differ-
entiation medium for 2 h at room temperature prior to cell 
seeding.
Phosphorylation assays
Immunoprecipitations of cell lysates bound with respec-
tive antibodies were conducted using Protein A/G agarose 
beads (Santa Cruz). Following SDS-PAGE separation and 
Western blotting, membranes were probed with anti-phos-
photyrosine antibodies (1:2500). Blots were subsequently 
stripped, blocked, and re-probed with antibodies binding 
the respective receptor. Receptor activation is represented 
by the ratio of relative optical densities (ROD) of phospho-
rylated vs. total protein.
RhoA GTPase activity assay
As in [2], RhoA activation was detected using a commer-
cial RhoA assay (Millipore).
TUNEL assay
To detect cell death, TUNEL assays (Promega) were con-
ducted and the percentage of apoptotic nuclei determined 
[2].
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Proliferation assay
The OPC were cultured in Sato’s differentiation medium 
for 24 h. Subsequently, cells were fixed and stained with 
Olig2 (1:1000) and PCNA (1:500). Number of cells was 
counted in random field with >200 cells per experiment. A 
minimum of three biological replicates were conducted.
Reverse transcriptase‑PCR and q‑RT PCR
RNA was extracted using RNeasy Mini Kit (Qiagen). 
Reverse transcription (first-strand cDNA synthesis kit for 
RT–PCR, Roche Applied Science) and second-round PCR 
was performed using GoTaq DNA polymerase (Promega). 
Primers used are summarized in Supplementary Table 7. 
q-RT-PCR was conducted on an Applied Biosystems 
7500HT Fast Real-time PCR system [2, 49]. Triplicate 
measurements were made on a minimum of three biologi-
cal replicates.
siRNA‑mediated gene‑silencing
siRNA transfections of purified OPCs were conducted with 
lipofectamine RNAiMAX transfection reagent (Invitrogen) 
in OPTI-MEM as in [2]. The knockdown efficiency was 
established by qPCR.
Animal experiments
Immunogold electron microscopy
Perfusion-fixed (4 % formaldehyde, 0.2 % glutaraldehyde) 
corpus callosum white matter was cryoprotected (2.3 M 
sucrose), mounted onto aluminium pins, and frozen in liq-
uid nitrogen. Ultrathin cryosections (Leica UC6 cryo-ultra-
microtome) were collected (2 % methylcellulose:2.3 M 
sucrose = 1:1), blocked (1 % BSA), and incubated with 
antibodies to EphrinB3 (1:200; R&D). Gold-conjugated 
secondary antibodies (Aurion) were used to visualize 
EphrinB3 epitopes on a LEO EM912 Omega transmis-
sion electron microscope (Zeiss) fitted with an on-axis 
2048 × 2048 CCD camera (Proscan).
EphrinB3 knockout mice
EphrinB3 knockout mice were kindly provided by Amparo 
Acker-Palmer and genotyped as previously [43].
Induction of focal demyelination
Female Sprague–Dawley rats were anesthetized with keta-
mine (75 mg/kg) and xylazine (10 mg/kg) and positioned in a 
stereotactic frame. Demyelination was induced bilaterally by 
stereotactic injection of ethidium bromide (0.01 %, 4 µl) into 
the CCP-young animals (10.4 mm caudal, 2.6 mm lateral and 
7.07 mm ventral to bregma) and older animals (11.1 mm cau-
dal, 2.8 mm lateral and 7.8 mm ventral to bregma).
Infusion of EphrinB3‑Fc‑IgG and anti‑EphrinB3 
antibodies into demyelinated lesions
EphrinB3 and anti-EphrinB3 antibodies were administered 
via osmotic pumps (ALZA Corporation) at 10 and 3 dpi, 
respectively (200 μg/ml in PBS). EphrinB3-Fc (R&D Sys-
tems) was pre-clustered with anti-human-Fc (Chemicon) 
for 2 h at room temperature (EphrinB3-Fc:anti-Fc = 10:1) 
prior to pump filling. Control animals received anti-Fc IgG 
only. Anti-EphrinB3 antibodies (R&D:Abcam ratio = 1:1). 
Controls received Human IgG. Animals were perfused at 
28 and 14 dpi, respectively.
Immunohistochemistry of CCP lesions
Rats were anesthetized and transcardially perfused with 
4 % PFA. The brains post-fixed, cryoprotected (30 % 
sucrose) and snap frozen. 15 µm cryostat sections were 
stained with antibodies to EphA4 (1:500), Nkx2.2 (1:150), 
β3tubulin (1:500).
In situ hybridization
In situ hybridization was conducted on cryostat sections 
using digoxigenin-labelled complementary RNA probes 
for Msrb, and Pdgfr-α as in [28, 49]. Lesions were identi-
fied on digital images of solochrome-cyanine-stained sec-
tions, and the lesion area was determined using Image J 
1.43b (http://rsb.info.nih.gov/ij/). ISH-stained cells in the 
lesions were counted on digitized adjacent sections. To rule 
out effects attributable to the size of the lesion, only lesions 
<0.4 mm2 were included for analysis [49].
Histological analysis of remyelination
Remyelination was assessed on tissue fixed with 4 % glu-
taraldehyde, osmicated and processed into resin (TAAB 
Laboratories) [28]. Sections (1 µm) were stained with meth-
ylene blue and Azur-II. Rank analysis was conducted as in 
[49]. Lesions with the greatest extent of remyelination were 
assigned the highest rank value. In addition, remyelinated 
and demyelinated axons were manually counted on a mini-
mum of 3 digitized 100x images of resin-embedded lesions.
Electron microscopy
Ultrathin sections (50 nm, Leica Ultracut S ultrami-
crotome) were stained with aqueous 4 % uranyl acetate and 
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lead citrate. Electron micrographs were obtained as out-
lined above [28, 49].
Statistical analysis/experimental design
All analyses were conducted with researcher blind to treat-
ment group. Experimental animals were randomized to 
treatment group. Data were analysed using GraphPad soft-
ware (Prism). Multiple group comparisons were conducted 
using one-way ANOVA followed by Dunnett’s post test. 
Two-tailed Student’s t test was used to test receptor acti-
vation, qPCR data. Cellular responses in vivo were ana-
lysed using Student’s t test. For rank analysis, a two-tailed 
Mann–Whitney U test was used.
Results
Human myelin extracts inhibit OPC differentiation
Inhibitory effects on OPC differentiation have been 
described for rodent [2, 41, 48] and porcine myelin [48]. 
We therefore first sought to establish that the OPC-differ-
entiation-inhibitory activity is also found in human myelin 
protein extracts (Fig. 1a–d). Assessment of OPCs cultured 
for 48 h on PLL control, rat and human myelin substrates 
confirmed strongly inhibited expression of the early dif-
ferentiation marker O4 and myelin basic protein (MBP), 
a protein expressed by mature oligodendrocytes. Further-
more, human myelin extracts also profoundly inhibited pro-
cess formation in OPCs (Fig. 1e–h). The effects of human 
myelin on OPC differentiation were specific, as TUNEL 
assays and cell counts did not reveal any differences from 
control substrates (Supplementary Fig. 1).
Identification of EphrinB3 as a myelin‑associated 
inhibitor of OPC differentiation
We previously demonstrated that the inhibitory activity of 
myelin is associated with the protein and not the lipid frac-
tion [48]. To identify the protein responsible for the inhibi-
tion, we developed a protocol for biochemical separation of 
protein fractions and enrichment of inhibitory activity. This 
fractionation included three steps: 1) enriching inhibitory 
activity by carboxymethyl (CM), 2) High Q column ion 
exchange chromatography, and 3) Sephadex S100 medi-
ated size exclusion (Supplementary Fig. 2). LC–MS/MS 
analysis of the inhibitory fractions followed by testing of 
candidate proteins with primary OPCs was not able to iden-
tify an inhibitory protein (Supplementary Table 1). Poten-
tial reasons why MS/MS identification was unsuccess-
ful include that the protein responsible for the inhibition 
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Fig. 1  Human myelin extracts contain selective inhibitors of OPC 
differentiation. a–d OPCs exposed to extracts of rat myelin extracts 
(rMPE) and human myelin preparations (hMPE) respond by down-
regulation of O4 and Mbp expression (2-day differentiation, n = 3; 
ANOVA: O4 ***P < 0.0001, Mbp ***P < 0.0001; Dunnett’s post hoc 
test PLL vs. rMPE: P < 0.0001; PLL vs. hMPE P < 0.0001). e–h The 
presence of hMPE also induced a reduction of the complexity of OPC 
processes and an increase of earlier morphological stages compared 
with OPCs plated on control substrate (2-day differentiation, n = 3; 
ANOVA: P < 0.0001; I mono/bipolar, II primary, III secondary, IV 
membranous branches). Error bars ± SEM. Scale bar in b–d and 
f–h = 30 μm
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might be either in low abundance or hydrophobic. As an 
alternative approach, we sought to estimate the size of the 
inhibitory protein, which would then facilitate a bioinfor-
matic search. For this purpose, fractions obtained following 
CM and High Q separation were spiked with two proteins 
of known molecular weight [immunoglobulin G (IgG), 
150 kDa, and lysozyme, 14 kDa] before they were further 
separated on S100 Sephadex size-exclusion columns. The 
addition IgG and lysozyme to protein fractions did not 
change the distribution of the inhibitory activity. Based on 
the localization of the inhibitory activity relative to the ref-
erence proteins, the size of the predicted protein was calcu-
lated to be approximately 51 kDa (Fig. 2a, Supplementary 
Fig. 2). Taking into account that post-translational modi-
fications may alter the size of the protein core, we con-
ducted PubMed Protein Database searches for signalling 
proteins expressed in the CNS that fall within a size range 
of 30–55 kDa (search terms: “030000:055000 [Molecu-
lar Weight] and membrane and signalling and ligand and 
brain”). From these searches, EphrinB1-B3, a group of 
transmembrane proteins forming part of the Ephrin fam-
ily, emerged as candidate proteins. We tested their effects 
on OPC differentiation by exposing cells to substrates 
prepared from EphrinB1-3. Amongst these, EphrinB3 had 
the most potent inhibitory effect on differentiation of oli-
godendrocyte linage cells (Fig. 2b). Immunoprecipitation 
of EphrinB3 in CNS, myelin extracts and column chroma-
tography fractions demonstrated enrichment of EphrinB3 
(and B1) in parallel with enrichment for OPC-differenti-
ation-inhibiting activity (Fig. 2f). The enrichment and the 
potent inhibitory effects observed implies an important 
role for EphrinB3. Nevertheless, other molecules may 
also contribute to the myelin-associated inhibition of OPC 
differentiation.
EphrinB3 inhibits OPC differentiation
Class B Ephrins can act both as ligands for Eph-receptor 
tyrosine kinases (RTKs) (forward signalling) and as recep-
tors for Eph-receptor binding (reverse signalling). Biologi-
cal functions of Ephrin signalling in the CNS include regu-
lation of axon outgrowth and migration of tumour and stem 
cells [4, 14, 15]. Expression of EphrinB3 has been noted 
in the developing CNS, where it has an important role 
preventing the crossing of corticospinal tract axons in the 
spinal cord and ensuring contralateral innervation of alpha-
motor neurons located in the ventral horns [17]. In the adult 
CNS, EphrinB3 is mainly expressed in white matter (http://
www.brainatlas.org), where it can be detected in oligoden-
drocytes [4]. We first confirmed the expression of EphrinB3 
in cultured oligodendrocyte lineage cells by immunocyto-
chemistry (Fig. 2g, h). Immunogold electron microscopy of 
murine corpus callosum white matter at 1 months of age 
suggested that EphrinB3 is located within myelin sheaths 
in the intact rodent CNS (Fig. 2i).
When OPCs were exposed to substrates containing 
recombinant EphrinB3-Fc fragments, in which the trans-
membrane segment was replaced with an Fc tag to make it 
soluble, a concentration-dependent impairment of O4 and 
MBP expression was detected (Fig. 2j–m). Furthermore, 
EphrinB3-Fc also negatively affected process formation 
and resulted in the majority of OPCs being arrested at an 
immature monopolar/bipolar stage (Fig. 2r–t). The effects 
of EphrinB3 on OPC differentiation were specific, as 
TUNEL assays and cell counts did not reveal any differ-
ences from control substrates (Supplementary Fig. 1).
Clustering EphrinB3 epitopes increases the inhibition 
of OPC differentiation
EphrinB-EphR signalling occurs by direct cell–cell inter-
actions and results in oligomerisation of receptor-ligand 
Fig. 2  EphrinB3 is associated with the inhibitory activity of myelin 
extracts and inhibits OPC differentiation in vitro. a Myelin protein 
extracts were separated into inhibitory fractions (red line percent-
age of O4+ cells cultured in the presence of individual fractions) 
using CM → HiqhQ → Sephadex S100 size-exclusion chromatog-
raphy (black line S100 chromatogram, grey line IgG and lysozyme 
peak). Fractions containing proteins with a calculated weight of 
51 kDal were associated with the highest inhibitory activity. b Bar 
graph showing the decrease of O4+ and Mbp+ oligodendrocyte 
lineage (OL) cells cultured in differentiation medium in the pres-
ence of recombinant human EphrinB1, B2, B3 (2-day differentiation, 
n = 3; ANOVA: O4 ***P < 0.0001, Mbp ***P < 0.0001; Dunnett’s 
post hoc test: PLL vs. EphrinB1 or EphrinB2 or EphrinB3 at 10 μg/
cm2: P < 0.0001). c–e Representative images of cells immunola-
belled for O4 (red) and MBP (green) cultured on control substrates 
(PLL) and EphrinB1, B2 substrates. f Immunoblot demonstrating that 
CM and subsequent HighQ column chromatography-based enrich-
ment of OPC-differentiation-inhibiting activity results in concord-
ant enrichment of EphrinB3 (brain total brain lysates, BSA bovine 
serum albumin). g, h EphrinB3 is expressed in immature OPCs 
(16 h differentiation), throughout to mature oligodendrocyte stages 
(3-day differentiation). i Electron microscopy immunogold labelled 
cryo-ultramicrotome sections of murine corpus callosum white mat-
ter at 1 months of age demonstrated the presence of EphrinB3 (red 
arrow) in myelin sheaths in vivo. j–m EphrinB3 inhibited OPC dif-
ferentiation in a dose-dependent manner (2-day differentiation, n = 3; 
ANOVA: O4 ***P < 0.0001, Mbp ***P < 0.0001; Dunnett’s post 
hoc test: PLL vs. MPE or vs. EphrinB3 at 2.5, 5, 10, 20 or 40 μg/
cm2: P < 0.0001. n RT-qPCR confirmed reduced expression of Mbp 
mRNA in the presence of EphrinB3 (n = 3; t test; **P < 0.001). o–q 
When OPCs were exposed to recombinant EphrinB3-Fc pre-clus-
tered with anti-Fc antibodies mimicking surface-bound EphrinB3, 
the inhibitory activity was increased (2-day differentiation; n = 3; 
ANOVA: Mbp ***P < 0.0001; Dunnett’s post hoc test: EphrinB3 vs. 
EphrinB3 + IgG-Fc at 1, 5 or 10 µg/ml): P < 0.0001. r–u EphrinB3 
also induced a reduction in the complexity of OPC processes and a 
corresponding increase of earlier morphological stages (2-day differ-
entiation; I mono/bipolar, II primary, III secondary, IV membranous 
branches) (n = 3; ANOVA: P < 0.0001). Error bars ± SEM. Scale 
bar in c–e, k–m, p–q = 30 μm, in i = 2 μm, in s–u = 20 μm
▸
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complexes. A particular feature of Ephrin signalling is 
that clustering of Ephrin-Eph receptors can modulate the 
signalling process. In most cases, ligand-receptor cluster-
ing leads to enhanced signalling [16]. To mimic interaction 
with membrane-bound EphrinB3, we exposed OPCs to 
aggregated EphrinB3-Fc using anti-Fc-IgG. Significantly 
fewer cells differentiated when exposed to pre-clustered 
EphrinB3 than non-clustered EphrinB3 (Fig. 2o–k).
EphrinB3 signals via EphA4 receptor and activates 
differentiation‑inhibiting intracellular cascades 
in OPCs
The B class of transmembrane Ephrins preferentially binds 
to EphB receptors. In addition, the EphA4 receptor can 
also recognize EphrinB3. We found that OPCs express 
EphB1-3 and EphA4 receptors at both the transcriptional 
and the protein levels (Fig. 3a–d, Supplementary Fig. 3). 
To investigate which of these receptors respond to the addi-
tion of recombinant EphrinB3-Fc to Sato’s differentiation 
medium, we conducted immunoprecipitation of OPC pro-
tein extracts with antibodies against individual Eph recep-
tors followed by Western blotting with anti-phosphotyros-
ine antibodies. This revealed a strong activation of EphA4 
and EphB2 receptors in response to EphrinB3-Fc (Fig. 3e–
h). However, EphB2 seemed to be expressed at relatively 
low levels in OPCs when compared to EphA4 expression 
(Supplementary Fig. 3).
Ephrin-Eph signalling has been associated with modu-
lation of Rho-GTPases. Myelin-associated inhibitors also 
activate RhoA signalling and inhibition of RhoA can 
neutralize inhibitory effects of myelin [2]. We therefore 
hypothesized that RhoA signalling might be activated in 
OPCs in response to EphrinB3. RhoA activity assays on 
OPCs cultured in the presence and absence of EphrinB3 
confirmed activation of RhoA in OPCs exposed to Ephrin 
B3 (Fig. 3i). In the past, we also demonstrated that mye-
lin protein extracts activate protein kinase C-α (Pkc-α) to 
mediate inhibitory effects on OPC differentiation, and that 
inhibition of Pkc-α promotes OPC differentiation in the 
presence of myelin [2]. Inhibitory PKC-α-mediated sig-
nalling is associated with phosphorylation and membrane-
to-cytosol translocation of Myristoylated alanine-rich 
C-kinase substrate (Marcks) and causes disorganization of 
the cytoskeleton and redistribution of actin filaments [2, 3]. 
We assessed the subcellular location of Marcks in OPCs 
and found that in the presence of EphrinB3 or myelin pro-
tein extract it was trapped in the cytosol, whereas on con-
trol substrate it was located at the membrane. This dem-
onstrated that EphrinB3 induces Pkc-α activity (Fig. 3j-l). 
Taken together, our findings indicate that EphrinB3 is suf-
ficient to explain activation of the inhibitory cascades in 
OPCs that have been associated with myelin extracts. In 
addition, we found that EphrinB3 also inhibited the activ-
ity of Focal adhesion kinase (Fak) (Fig. 3m), a positive 
regulator of early OPC differentiation [21] that has been 
implicated in Ephrin-EphA4 signalling [8].
To assess transcriptional consequences of Ephrin signal-
ling in OPCs, we investigated the expression of Nkx2.2, a 
functionally important transcription factor that is known to 
be up-regulated at the onset of OPC differentiation [19], 
but whose expression fails to increase in the presence of 
myelin extracts in vitro [48] and in vivo [28]. We found 
reduced expression of Nkx2.2 in the presence of EphrinB3 
(Fig. 3n,o).
Assessment of the effects of EphrinB3 on CNS 
remyelination in vivo
Having established an important regulatory function of 
EphrinB3 on OPC differentiation in vitro, we assessed the 
effects of EphrinB3 on myelin regeneration in vivo. For this 
purpose, we used a well-characterized model of remyelina-
tion, in which a focal demyelination lesion is induced by 
stereotactic injection of ethidium bromide into the rat cau-
dal cerebellar peduncle (CCP) (Supplementary Fig. 4 a,b). 
This results in rapid demyelination and recruitment of new 
OPCs. Around day 10 post lesion induction, the recruited 
OPCs start to differentiate into myelin-forming oligoden-
drocytes. 28 days post lesion induction, the lesions are fully 
remyelinated [28, 53].
Fig. 3  EphrinB3 activates RhoA and Pkc-α, inhibits Fak, and 
decreases Nkx2.2 expression. a–d OPCs in culture for 48 h expressed 
EphA4, EphB1, EphB2 and EphB3 receptor tyrosine kinases (RTKs). 
e–h EphrinB3-induced phosphorylation of EphA4 and EphB2 RTKs 
in OPCs [immunoprecipitation followed by WB, pTyr phosphoryl-
ated Eph-RTK, t-Eph total Eph-RTK, quantification of phosphoryl-
ated Eph-RTK relative to total Eph-RTK (ROD), n = 3: t test; EphA4 
***P < 0.05; EphB1 P > 0.1; EphB2 **P < 0.01; EphB3 P > 0.1]. 
i Furthermore, EphrinB3-induced RhoA activity in OPCs (24-h dif-
ferentiation; quantification of RhoA-GTP relative to RhoA-GDP 
(ROD), n = 3: ANOVA; *P < 0.05). j–l Whilst Marcks is localized at 
the membrane in differentiating OPCs cultured on control substrates, 
EphrinB3-mediated activation of Pkc-α resulted in phosphoryla-
tion and membrane-to-cytosol translocation of Marcks. m EphrinB3 
also inhibited the activation of Fak [quantification of phosphorylated 
(p-)Fak relative to total (t-)Fak: (ROD), n = 3; t test; **P < 0.001]. 
n, o Similar to MPE, EphrinB3 inhibited Nkx2.2 expression in 
OPCs (24-h differentiation, n = 3; ANOVA; ****P < 0.0001; Dun-
nett’s post hoc test PLL vs. MPE: P < 0.001; PLL vs. EphrinB3: 
P < 0.001; 3-day differentiation, n = 3; ANOVA; ****P < 0.0001; 
Dunnett’s post hoc test PLL vs. MPE: P < 0.001; PLL vs. EphrinB3: 
P < 0.001). p Proposed model of EphrinB3 signalling regulating 
OPC differentiation: the presence of EphrinB3 activates EphA4 and 
EphB2-RTKs. This results in activation of RhoA and Pkc-α signal-
ling, both known to inhibit OPC differentiation. EphrinB3 also inhib-
its Fak signalling, a positive regulator of OPC differentiation. Failed 
differentiation is associated with reduced expression of Nkx2.2. Error 
bars ± SEM. Scale bar in a–d = 40 µm, j–l = 20 μm
▸
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OPCs express EphA4 receptor in models of CNS 
remyelination and human MS lesions
We first investigated whether OPCs can respond to 
EphrinB3 in demyelinated lesions by assessing the expres-
sion of EphA4 receptor in CCP lesions (Fig. 4a–c). A 
large number of Nkx2.2+ OPCs were immunoreactive for 
EphA4. However, as expected, EphA4 expression was not 
restricted to OPCs. To confirm expression of EphA4 in the 
context of human MS, we conducted immunohistochemi-
cal stainings on postmortem CNS white matter tissue con-
taining chronic active MS lesions. This confirmed that 
Nkx2.2+ OPCs express EphA4 receptors in MS lesions 
(Fig. 4d).
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EphrinB3 infusion does not affect the recruitment 
of OPCs
To assess the effects of EphrinB3 on remyelination, 
EphrinB3-Fc pre-clustered with anti IgG-Fc (to mimic 
the surface-bound presentation of EphrinB3 on myelin 
debris) was stereotactically infused into the CCP, start-
ing at 10 days post lesion induction (dpi), and compared 
with controls infused with IgG-Fc (and vehicle-PBS only) 
(Fig. 4n). Successful delivery of recombinant EphrinB3-Fc 
was confirmed by immunohistochemistry (Supplementary 
Fig. 4e). Quantification of OPCs by in situ hybridisation 
using probes to platelet-derived growth factor α-positive 
(Pdgfr-α+) did not reveal any differences between 
EphrinB3-exposed and control animals (Fig. 4e–h).
EphrinB3 does not alter the presence of macrophages
Because the innate immune response plays an important 
role in remyelination [29], we also assessed the number 
of macrophages positive for Macrophage scavenger recep-
tor B (Msrb). We found that infusion of pre-clustered 
EphrinB3-Fc did not induce any changes in the number of 
macrophages (Fig. 4i–l).
EphrinB3 inhibits CNS remyelination
The extent of remyelination at 28 dpi was assessed on 
semithin resin sections (Fig. 4m–p). As expected at this 
time point, remyelination in control animals was almost 
complete [53] with the majority of axons bearing thin 
myelin sheaths that are characteristic of remyelination [7] 
(Fig. 4o). In contrast, in lesions infused with EphrinB3-Fc, 
the majority of axons remained demyelinated (Fig. 4p). A 
significant difference was found between the groups by 
investigator-blinded rank analysis [28, 49] (Fig. 4m) and 
quantification of remyelinated and demyelinated axons 
(Fig. 4n, Supplementary Fig. 5a). The density of axons in 
the lesions was comparable (Supplementary Fig. 5SB). 
Stereotactic administration of pre-clustered EphrinB3-Fc 
into intact CCP white matter did not affect the integrity of 
mature myelin sheaths, as we could not detect any changes 
in naive (non-lesioned) CCPs following infusion (Supple-
mentary Fig. 5Sd).
The absence of EphrinB3 accelerates developmental 
myelination
The results so far demonstrate that EphrinB3 and its recep-
tor EphA4 are expressed throughout the oligodendrocyte 
lineage and that the presence of extrinsic EphrinB3 medi-
ates inhibitory effects on the differentiation of OPCs. We 
next analysed developmental myelination in EphrinB3-
deficient mice and found more myelinated axons in the 
corpus callosum at 1 month in EphrinB3-deficient mice 
than wild-type mice (Fig. 5e–h). The relative thickness of 
myelin sheaths as measured by G ratios was the same in 
wild-type and knockout mice (Fig. 5a–d). At 3 months, the 
number of myelinated axons was comparable amongst the 
groups (Fig. 5e–g), indicating that loss or EphrinB3 results 
in accelerated myelination without affecting myelin thick-
ness or the final extent of myelination.
Antibody‑mediated masking of EphrinB3 epitopes 
neutralizes the inhibitory effects of myelin extracts 
on OPC differentiation
To investigate the role of EphrinB3 with respect to the 
OPC-differentiation-inhibiting effects of myelin, we 
exposed OPCs to myelin protein extracts from EphrinB3 
Ko mice and wild-type littermates (Fig. 6a). Myelin protein 
extract (MPE) from EphrinB3-deficient mice was signifi-
cantly less inhibitory than wild-type MPE.
To determine whether antibody-mediated masking of 
EphrinB3 epitopes could represent a viable therapeutic 
approach, myelin protein extracts were treated with two 
different commercially available antibodies directed against 
two distinct peptide sequences of EphrinB3 (Fig. 6h). Both 
antibodies induced O4 and MBP expression of OPCs that 
were plated on the antibody-bound substrates (Fig. 6a–d). 
A combination of the two antibodies resulted in neutraliza-
tion of the inhibitory effects of myelin, restoring OPC dif-
ferentiation to levels observed in cells plated on PLL con-
trol substrate.
Fig. 4  The presence of EphrinB3 inhibits CNS remyelination. a–d 
EphA4 receptor is expressed by Nkx2.2+ OPCs and βIII-tubulin+ 
axons in experimental CCP lesions, as well as d in chronic active 
human white matter MS lesions. e–h In situ hybridization for Pdgfr-α 
showed comparable OPC densities within lesions of EphrinB3-treated 
animals and controls 28 days after lesion induction (dpi) (10 dpi—
prior to EphrinB3 infusion: n = 11; IgG-Fc: n = 6; EphrinB3 + IgG-
Fc: n = 12; ANOVA: P > 0.1). i–l Similarly, levels of Msrb+ mac-
rophages remained unaffected (10 dpi: n = 9; IgG-Fc: n = 7; 
EphrinB3 + IgG-Fc: n = 11; ANOVA: P > 0.1). m–t The extent of 
remyelination was assessed on methylene blue and Azur-II-stained 
semithin sections. EphrinB3 infusion induced a significant impair-
ment of CNS remyelination as compared to controls (IgG-Fc con-
trol n = 6; EphrinB3 n = 5; Mann–Whitney U test; **P < 0.001). n 
Quantification of demyelinated and demyelinated axons confirms that 
the presence of EphrinB3 impairs CNS remyelination (PBS control 
n = 5, IgG-Fc control n = 6; EphrinB3 n = 5; t test; ***P < 0.0001). 
o Remyelination in controls was nearly complete at 28 dpi; how-
ever, p in EphrinB3-infused animals, the majority of axons remained 
demyelinated. q, r EM analysis demonstrated successful formation of 
compact myelin sheaths in controls, whereas s, t in EphrinB3-infused 
lesions axons remained demyelinated. t Occasionally, axons were 
contacted by oligodendroglial processes in EphrinB3-treated animals 
that failed to form compact myelin. Error bars ± SEM. Scale bar in 
a = 30 μm; in b, c = 50 μm; in d = 40 μm; in f–h, j–l = 200 μm; in 
o, p = 100 μm; in q, r = 2 μm; in s, t = 0.5 μm
◂
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Antibody‑mediated neutralization of EphrinB3 
promotes CNS remyelination
Focal areas of demyelination were induced using eth-
idium bromide in the CCPs of 9 to 12-month-old female 
Sprague–Dawley rats. Owing to their greater age, remyeli-
nation was expected to be less efficient and delayed. Aged 
animals serve as a clinically relevant model for remyeli-
nation in young to middle-aged adults [25, 42]. Stereo-
tactic infusion of anti-EphrinB3 antibodies was initiated 
at 3 dpi. Remyelination was assessed on semithin resin-
embedded sections at 14 dpi (Fig. 6e–h). As expected, 
remyelination in control animals that received infusions 
of control-IgG, or PBS alone was limited. In contrast, 
widespread remyelination was detected in animals that 
received anti-EphrinB3 antibodies. The increase in remy-
elination was confirmed by both, histological rank analy-
sis and manual counts of axons within the lesions. Assess-
ment of the lesions by electron microscopy (Fig. 6h) 
confirmed the presence of thin myelin sheaths typical for 
remyelination throughout the lesions in anti-EphrinB3-
treated animals. Axons in control lesions remained largely 
demyelinated (Supplementary Fig. 5 g), but the relative 
density of axons between the groups was comparable 
(Supplementary Fig. 5d). Our data demonstrate that the 
administration of EphrinB3 antibodies did not alter the 
number of OPCs but instead enabled efficient differentia-
tion (Fig. 6i–j).
MS lesions contain EphrinB3
Because EphrinB3 in the adult CNS is predominantly 
expressed by oligodendrocytes, the main source of EphrinB3 
present in MS white matter lesions is likely to be myelin 
debris that accumulates as a consequence of demyelina-
tion. Experimental findings demonstrated that the clearance 
of myelin debris is mediated by macrophages [28]. In MS, 
the presence of foamy macrophages defines the acute lesion 
stage. As time passes, macrophages disappear from the 
lesions whilst other inflammatory cells continue to persist. 
This demarcates the subacute, or chronic active lesion stage. 
Chronic (silent) lesions are defined by the complete absence 
of immune cells [30]. Investigating the presence of myelin 
proteins including EphrinB3 in subacute (chronic active) 
lesions therefore would be useful to determine (1) the effi-
ciency of macrophage-mediated clearance of myelin debris, 
and (2) whether myelin-associated inhibitors are present for 
prolonged time periods at biologically relevant levels.
To address these questions, we prepared protein extracts 
from laser capture-microdissected acute (active) and 
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Fig. 5  Accelerates developmental myelination in EphrinB3 knock-
out mice. a–d 30 days post partum significantly more axons in the 
corpus callosum of EphrinB3−/− mice were myelinated as compared 
to WT animals. This was accompanied by a corresponding decrease 
in the number of nude axons. The relative thickness of the myelin 
sheaths (G ratios) remained unchanged (WT: n = 9; EphrinB3−/−: 
n = 9; ANOVA: ***P < 0.0001). e–g After 3 months, the number 
of the myelinated axons in the corpus callosum in wild-type and 
EphrinB3−/− mice were comparable (WT: n = 5; EphrinB3−/−: 
n = 5; ANOVA: P > 0.1). Error bars ± SEM. Scale bar in c, d, g, 
h = 3 μm
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subacute (chronic active) MS lesions. The lesions were 
visualized on fresh-frozen postmortem tissue using a rapid 
immunohistochemistry protocol for myelin oligodendro-
cyte glycoprotein (MOG) (Supplementary Fig. 6b). During 
the dissection, care was taken to avoid the MOG-positive 
normal-appearing white matter.
We first asked whether protein extracts from subacute 
(chronic active) MS lesions contain EphrinB3. Immuno-
blots with antibodies specific to EphrinB3 confirmed the 
presence of EphrinB3 MS lesions (Fig. 7c). Furthermore, 
proteomic analysis of the lesion extracts demonstrated high 
levels of myelin proteins in demyelinated lesions (Fig. 7a, 
b; Supplementary Tables 2–6).
To confirm that the axons within the lesions were indeed 
demyelinated, electron micrographs were obtained from 
sections of the same lesions. As expected from the absence 
of MOG staining, the axons within the lesions were 
denuded and only very few remnants of myelin sheaths 
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P > 0.05; Olig2-CC1). Representative images from control k and 
EphrinB3 antibody infused lesions l at 14 days post lesion induction 
stained for Olig2 and CC1. i Infusion of EphrinB3-specific antibod-
ies (Ab1 + 2) into CCP lesions also accelerated CNS remyelina-
tion as evident from the rank analysis 14 dpi [control-IgG: n = 8, 
EphrinB3-Ab(1 + 2): n = 5, Mann–Whitney U test **P < 0.01]. j 
Manual quantification of remyelinated and demyelinated axons 
within lesions confirmed accelerated remyelination in Anti-EphrinB3-
treated animals [control-IgG: n = 4, EphrinB3-Ab(1 + 2): n = 4, t 
test **P < 0.01]. k, l Electron micrographs demonstrating enhanced 
remyelination in EphrinB3-Ab(1 + 2) infused lesions as compared to 
IgG controls. Error bars ± SEM. Scale bar in c, d = 30 μm; in g, 
h = 200 μm (in inset = 50 μm), in k, l = 5 μm
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Fig. 7  EphrinB3 is present in MS lesions and its neutralization pro-
motes OPC differentiation. a Proteins in laser-microdissected tis-
sue of MS lesions were identified using mass spectrometry. The 
relative abundance of individual myelin-associated proteins (red 
bars) detected in peri-lesional white matter (WM1, 2), normal-
appearing white matter (MS1WM), and chronic active MS lesions 
(MS1-3) was comparable. This indicates that the phagocytosis of 
myelin debris in MS lesions remained incomplete. b Western blots 
confirmed the presence of myelin proteins (MBP, PLP) in chronic 
active MS lesion extracts. c EphrinB3 was detected in human white 
matter (WM1, 2) and chronic active MS lesion extracts (MS1-3) by 
immunoprecipitation and Western blotting. d–g OPCs cultured on 
extracts of chronic active MS lesions (MS1–3) and human white mat-
ter (WM1, WM2) show reduced O4 + and Mbp + expression com-
pared to OPCs plated on control substrates (poly-l-lysine, PLL) and 
human skin extracts (hSkin) (2-day differentiation, n = 3; ANOVA: 
O4 ***P < 0.0001, Mbp ***P < 0.0001; Dunnett’s post hoc test: 
PLL vs. WM and MS extracts: P < 0.0001; PLL vs. hSkin: P > 0.05). 
h–k Neutralization of EphrinB3 in acute MS lesion extracts (AL1-
3) using antibodies raised against two distinct EphrinB3 epitopes 
(Ab1, Ab2) induced OPCs differentiation into O4 + and Mbp + oli-
godendrocytes as compared to treatment with unspecific antibodies 
(IgG); (n = 3; ANOVA: O4 ***P < 0.0001, Mbp ***P < 0.0001; 
Dunnett’s post hoc test; MPE vs. MPE + Ab1 and Ab2: P < 0.0001; 
MPE vs. MPE + IgG; P > 0.1). l–o Similarly, treatment of chronic 
active MS lesion extracts (MS1–3) with EphrinB3-specific antibod-
ies (Ab1, Ab2) significantly increased in the percentage of O4 + and 
Mbp + OPCs as compared to IgG controls (n = 3; ANOVA: O4 
***P < 0.0001, Mbp ***P < 0.0001; Dunnett’s post hoc test; 
MPE vs. MPE + Ab1 and Ab2: P < 0.0001; MPE vs. MPE + IgG; 
P > 0.1). Error bars ± SEM. Scale bar in e–g, i–k, m–o = 30 μm
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were found in association with individual axons (Sup-
plementary Fig. 6f–h). As phagocytosing cells were not 
detected in the lesions, macrophage-ingested myelin can-
not account for the myelin-associated proteins identified 
by mass spectrometry. However, in all images obtained 
of all the lesions investigated, the presence of extracellu-
lar granular material was noted. In some areas, this was 
distributed diffusely, in other areas clumped together in 
small pockets between cellular processes (Supplemen-
tary Fig. 6f, g). In the absence of intact myelin sheaths 
and phagocytic cells, the myelin proteins detected were 
most likely associated with this interstitial debris. These 
findings support the hypothesis that demyelination in MS 
results in accumulation of extracellular myelin debris [30]. 
Moreover, the fact that EphrinB3 (and other myelin mol-
ecules) were found in subacute lesions indicated that the 
phagocytic clearance of myelin debris in MS lesions may 
remain incomplete.
The molecular environment of early MS lesions inhibits 
OPC differentiation
We next sought to investigate whether EphrinB3 was pre-
sent in MS lesions at biologically relevant levels. A number 
of OPC inhibiting factors have been identified, which seem 
to be re-expressed in MS lesions. However, the impact of 
the molecular environment of MS lesions on OPC differ-
entiation has not yet been studied [1, 12, 13, 27, 30, 51]. 
We therefore cultured OPCs on substrates prepared from 
the extracts from acute and subacute MS lesions. Unlike 
control protein extracts from human skin samples or poly-
l-lysine (PLL)-only controls, active and chronic active 
MS lesion extracts induced a significant inhibition of OPC 
differentiation (Fig. 7a–d) (extracts from normal-appear-
ing CNS white matter were included as inhibitory con-
trols. Due to the presence of myelin proteins, these were 
expected to inhibit OPC differentiation). TUNEL assays 
demonstrated that the MS lesion extracts specifically inhib-
ited OPC differentiation as no differences in cell survival 
were detected (Supplementary Fig. 7d, e).
Neutralization of EphrinB3 epitopes in MS lesion 
extracts promotes OPC differentiation
Our data provide the first direct evidence that the molecular 
milieu of MS lesions inhibits the differentiation of OPCs. 
But how important is the contribution of EphrinB3 to the 
differentiation-inhibiting environment of MS lesions?
To address this question, we investigated the effects of 
antibody-mediated masking of EphrinB3 epitopes in MS 
lesions. OPCs were cultured on lesion extracts from acute 
and subacute (chronic active) lesions that were incubated 
with antibodies binding EphrinB3 or unspecific IgG.
We found that treatment of anti EphrinB3-antibodies 
efficiently reduced the inhibitory effects of acute MS 
lesion extracts (Fig. 7h–k). Consistent with the presence of 
EphrinB3 in chronic active lesions, we found that treatment 
with anti EphrinB3-antibodies was also able to induce OPC 
differentiation on extracts from later lesion stages (Fig. 7l–
o). However, the inhibitory activity in chronic active lesions 
was less pronounced. This may be in part explained by the 
different lysis buffer used for extraction of proteins, which 
also allowed for proteomic analysis of the lesion content. 
An alternative hypothesis is that the lesion composition, 
and specifically the presence of OPC differentiation inhibi-
tors in MS lesions changes over time [30]. In conclusion, 
our data suggest that inhibitory effects of myelin debris 
accumulating in acute MS lesions can be neutralized by 
antibody-mediated masking of EphrinB3 epitopes.
Discussion
We and others have in the past demonstrated that the 
innate immune system plays an important role in the pro-
cess of CNS remyelination. [29, 37]. Apart from the secre-
tion of cytokines [31, 37, 44], the phagocytic removal of 
myelin debris by macrophages is an essential prerequisite 
for successful remyelination in experimental models [28]. 
However, the factors in myelin responsible for the OPC 
differentiation block remained unknown. In the present 
manuscript, we demonstrate that EphrinB3 plays an impor-
tant role in the myelin-related inhibition of OPCs. Ephrin 
signalling in OPCs has not yet been investigated in detail: 
a previous study has implicated Ephrin signalling in OPC 
migration [40]. Our data indicate that EphrinB3 induces 
a concentration-dependent inhibition of OPC differentia-
tion in vitro. Furthermore, highly reminiscent to the infu-
sion of myelin extracts [28], the addition of EphrinB3 into 
demyelinating lesions resulted in a nearby complete block 
of remyelination in the toxin model used. Conversely, 
genetic elimination or antibody-mediated neutralization 
of EphrinB3 epitopes decreased the inhibitory activity of 
myelin extracts on OPCs, promoted OPC differentiation 
in vitro and during development in vivo, and accelerated 
CNS remyelination in vivo. Finally, our data demonstrate 
that acute and subacute MS lesion extracts contain inhibi-
tors of OPC differentiation that can be partially neutralized 
by blocking EphrinB3 epitopes.
Together with NogoA, OMgp, and MAG, EphrinB3 
is known as a myelin-associated inhibitor of neurite out-
growth [4, 18]. This is in contrast to our findings in the 
oligodendrocyte lineage where only EphrinB3 negatively 
affected OPC differentiation whereas NogoA, OMgp and 
MAG did not [48]. Ephrin-Eph signalling is character-
ized by high levels of redundancy. Although we found that 
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EphA4-RTK is responsive to EphrinB3 and expressed at 
significant levels in OPCs, it is possible that other recep-
tors may also play a role. A specific importance of EphA4 
in mediating EphrinB3 signals is suggested by the phe-
notypic similarities of EphrinB3-knockout and Eph4A-
knockout mice, which both display similar “hopping” 
behaviour due to axonal divergence as a consequence of 
the lost midline barrier in the developing spinal cord [33]. 
Genetic disruption of EphrinB3-EphA4 signalling results 
in aberrant axonal sprouting, and aberrant corticospinal 
tract innervation due to the absence of inhibitory midline 
cues in the developing spinal cord. As a consequence, 
mice lacking EphrinB3 or EphA4 are unable to control 
their hindlimbs independently. Our study is the first dem-
onstrating that EphrinB3-ko mice also exhibit changes in 
myelination.
We found that the presence of EphrinB3 induced inhibi-
tory RhoA and PKCα signalling in OPCs. In the past, we 
demonstrated that both cascades are responsible for the 
differentiation-inhibiting effects of myelin preparations, 
and that modulation these cascades is able to overcome 
the differentiation block mediated by myelin in OPCs. A 
drawback of the present study is that it does not investigate 
whether a causal relationship exists between RhoA and 
PKCα and the inhibitory effects of EphrinB3 on OPC dif-
ferentiation. Instead, our priority was to investigate whether 
neutralizing its effect affects OPC differential and CNS 
remyelination and to clarify its role in MS lesions.
The notion that EphrinB3 plays an important role for 
the myelin-associated inhibition of OPC differentiation is 
further supported by the increasing presence of EphrinB3 
in sub-fractioned myelin extracts enriched for inhibitory 
activity. Furthermore, we found that the inhibitory activity 
in myelin extracts generated from EphrinB3 ko mice was 
reduced but not completely eliminated. Genetic deletion 
of EphrinB3 is known to result in a compensatory increase 
of EphrinB1 and EphrinB2 expression [43]. EphrinB1 
and B2 also inhibit OPC differentiation, albeit to a lesser 
extent (Fig. 2b). It is therefore not surprising that residual 
inhibitory activity was found in myelin from EphrinB3-ko 
animals.
A number of findings indicate that EphrinB3 also plays 
an important role in the differentiation block occurring in 
MS. Failure of CNS remyelination in MS lesions has been 
associated with a poorly understood inability of OPCs to 
differentiate into myelin-forming oligodendrocytes [11, 
32]. It has been proposed that both intrinsic and extrinsic 
factors are responsible for this failure of OPC differentia-
tion. So far the evidence that extrinsic factors may play a 
role for the differentiation block in MS was limited to 
detecting their expression in subacute and chronic MS 
lesions [1, 12, 13, 27, 30, 51]. In contrast, our data provide 
the first direct evidence that the molecular environment of 
MS lesions is inhibitory for OPC differentiation. We found 
that antibody-mediated masking of EphrinB3 epitopes 
was able to partially neutralize the inhibitory effects of the 
lesion environment on OPCs. It is likely that other extrin-
sic factors, including, e.g. hyaluronan also contribute to 
the inhibition of OPCs in MS lesions [1, 46]. Our results 
emphasize the importance of the lesion environment for the 
success of remyelination, which must be taken into account 
when devising therapeutic strategies aimed at promoting 
myelin regeneration in MS.
In conclusion, our findings suggest that EphrinB3 
may be a relevant target for promoting remyelination 
in demyelinating disease. Ephrin-Eph-RTK signalling 
lends itself to pharmacological intervention at the levels 
of ligand-receptor binding, receptor kinases and down-
stream signalling effectors. Several compounds interfer-
ing with downstream signalling pathways (such as the 
RhoA pathway) have entered the clinical testing stage. 
Small molecules and other pharmacological agents act-
ing at the ligand-receptor and receptor-RTK levels are 
currently being developed [39]. Finally, the application 
of EphrinB-neutralizing antibodies could also be con-
sidered, as accumulation of myelin debris occurs dur-
ing active lesion stages that are associated with an open 
blood–brain barrier [36].
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